What does this research mean for the field?

There are significant disparities across the UK and Ireland in access to medical therapies, deroofing procedures, and multidisciplinary team support for patients with hidradenitis suppurativa. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The study aims to assess current secondary care management practices for hidradenitis suppurativa in the UK and Ireland.

March 18, 2026Open Access

Secondary care management of patients with hidradenitis suppurativa in the United Kingdom and Ireland: a survey of current practice

Key Points

The study aims to assess current secondary care management practices for hidradenitis suppurativa in the UK and Ireland.
Survey distribution among secondary care providers
Assessment of access to medical therapies
Evaluation of multidisciplinary team (MDT) support
Highlights disparities in access to hidradenitis suppurativa treatments
Identifies need for improved care standardisation
Reports on the role of a new National HS MDT run by H-SKIN in improving access to support

Abstract

The results highlight UK disparities in access to HS medical therapies, deroofing and MDT support. Improvements in the standardisation of care are needed. The new National HS MDT run by H-SKIN will help to facilitate this by improving access to specialist support.

Secondary care management of patients with hidradenitis suppurativa in the United Kingdom and Ireland: a survey of current practice

Key Points

Abstract

Cite This Study